OMRF researchers have identified a compound that has been successfully shown to decrease both tumor size and tumor vasculature in animal models of Glioblastoma Multiforme (GBM), an aggressive type of malignant brain tumor.

Year Founded: 2012

Year Partnered: 2012

Category: Biotech/Pharma

Fund: Oklahoma Seed Capital Fund  

Acquired in 2016 by Oblato, Inc.